Literature DB >> 6892984

Curability of advanced Hodgkin's disease with chemotherapy. Long-term follow-up of MOPP-treated patients at the National Cancer Institute.

V T DeVita, R M Simon, S M Hubbard, R C Young, C W Berard, J H Moxley, E Frei, P P Carbone, G P Canellos.   

Abstract

The results of treatment of 198 patients with Hodgkin's disease with MOPP (mechlorethamine, vincristine, procarbazine, and prednisone) were analyzed. Eighty percent attained complete remission, and 68% of patients achieving a complete remission have remained disease free beyond 10 years from the end of treatment. Results of autopsy on patients who died of other causes while in clinical complete remission did not show evidence of residual tumors except in one patient. Asymptomatic patients and patients with mixed-cellularity or lymphocytic-depleted Hodgkin's disease do significantly better than symptomatic patients and those with nodular sclerosing histologic type. Advanced Hodgkin's disease appears to be curable by chemotherapy.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6892984     DOI: 10.7326/0003-4819-92-5-587

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN: 0003-4819            Impact factor:   25.391


  47 in total

1.  Hodgkin's Disease 1985.

Authors:  R E Myers; J S Ginsberg
Journal:  Can Fam Physician       Date:  1985-06       Impact factor: 3.275

Review 2.  State of the art in the treatment of Hodgkin lymphoma.

Authors:  Peter Borchmann; Dennis A Eichenauer; Andreas Engert
Journal:  Nat Rev Clin Oncol       Date:  2012-06-12       Impact factor: 66.675

Review 3.  Gemcitabine and other new cytotoxic drugs: will any find their way into primary therapy?

Authors:  David W Dougherty; Jonathan W Friedberg
Journal:  Curr Hematol Malig Rep       Date:  2010-07       Impact factor: 3.952

4.  Targeted therapy and hematological malignancy.

Authors:  James O Armitage
Journal:  Target Oncol       Date:  2009-02-14       Impact factor: 4.493

5.  Prognostic value of response after three MOPP cycles in Hodgkin's disease--stage III and IV.

Authors:  M Monconduit; H Tilly; J F Menard; R Le Fur; A Barbot; H Piguet
Journal:  Blut       Date:  1987-03

6.  A Historical Tale of Two Lymphomas: Part I: Hodgkin lymphoma.

Authors:  Ritu Lakhtakia; Ikram Burney
Journal:  Sultan Qaboos Univ Med J       Date:  2015-05-28

7.  Tumor-Targeted Synergistic Blockade of MAPK and PI3K from a Layer-by-Layer Nanoparticle.

Authors:  Erik C Dreaden; Yi Wen Kong; Stephen W Morton; Santiago Correa; Ki Young Choi; Kevin E Shopsowitz; Kasper Renggli; Ronny Drapkin; Michael B Yaffe; Paula T Hammond
Journal:  Clin Cancer Res       Date:  2015-06-01       Impact factor: 12.531

8.  An effective oral combination in advanced relapsed Hodgkin's disease prednisolone, etoposide, chlorambucil and CCNU.

Authors:  A L Lennard; P J Carey; G H Jackson; S J Proctor
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

Review 9.  Factors in improved survival from paediatric cancer.

Authors:  J W Taub
Journal:  Drugs       Date:  1998-11       Impact factor: 9.546

10.  Classical Hodgkin's lymphoma in adults: guidelines of the Italian Society of Hematology, the Italian Society of Experimental Hematology, and the Italian Group for Bone Marrow Transplantation on initial work-up, management, and follow-up.

Authors:  Ercole Brusamolino; Andrea Bacigalupo; Giovanni Barosi; Giampaolo Biti; Paolo G Gobbi; Alessandro Levis; Monia Marchetti; Armando Santoro; Pier Luigi Zinzani; Sante Tura
Journal:  Haematologica       Date:  2009-03-10       Impact factor: 9.941

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.